Last mentioned: Mar 17, 2026
Settlement Reached
Both companies announce an end to litigation and the start of a strategic collaboration.
Supply Stabilization
Novo Nordisk increases supply of branded Wegovy, challenging the legal basis for compounding.
Hims Enters Market
Hims & Hers launches its compounded semaglutide offering at a lower price point.
Litigation Begins
Novo Nordisk starts filing lawsuits against compounding pharmacies for IP infringement.
Hims & Hers Health shares skyrocketed 41% following a strategic agreement with Novo Nordisk to distribute branded GLP-1 medications, including Ozempic, directly through its telehealth platform. The deal effectively ends a high-stakes patent dispute and transitions the company away from controversial compounded formulations toward FDA-approved branded therapies.
Hims & Hers Health and Novo Nordisk have settled their legal dispute regarding compounded weight loss medications, transitioning into a strategic collaboration. This agreement marks a significant shift in the GLP-1 market, moving from litigation to a partnership that could broaden access to semaglutide treatments.
This page surfaces every story mentioning Hims & Hers Health across our biotech coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running biotech beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where Hims & Hers Health was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |